Formosa Pharmaceuticals is a preclinical and clinical stage biopharmaceutical company with focus in the therapeutic areas of ophthalmology, oncology, and anti-infectives.
- Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
- Formosa Pharmaceuticals Announce FDA Acceptance of NDA Filing for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
- Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
Formosa Pharma is developing a unique pipeline consisting of risk-diverse development modes, including 505(b)(2), biosimilars, and NCEs. Our proprietary APNT™ nanoparticle formulation platform, from which lead program APP13007 is derived, is available for application to drug candidates in need of improving pharmacokinetics and bioavailability.